| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Not a direct drug target; serves as a biomarker for Smith-Lemli-Opitz syndrome (SLOS).
|
|---|---|
| ln Vitro |
In vitro, 8-dehydrocholesterol is used as a research tool to study cholesterol biosynthesis and metabolism. It serves as a diagnostic biomarker for SLOS, reflecting altered cholesterol metabolism and oxidative stress. The compound does not act as a direct drug target itself. It accumulates when 7-dehydrocholesterol reductase (DHCR7) activity is deficient.
|
| ln Vivo |
In vivo, elevated levels of 8-dehydrocholesterol are a diagnostic biochemical feature of Smith-Lemli-Opitz syndrome (SLOS). The compound accumulates in tissues and plasma in patients with SLOS. It is used as a biomarker for diagnosis and monitoring of SLOS.
|
| Enzyme Assay |
8-Dehydrocholesterol is a sterol compound used as a reference standard for analytical method development. No specific enzyme/receptor binding assays are applicable as the compound functions as a biomarker rather than a drug target. For chromatographic analysis, the compound is dissolved in appropriate solvent and analyzed by HPLC or GC-MS. Sterol profiling assays are performed using plasma or tissue samples: lipids are extracted with organic solvents, saponified, and sterols are derivatized for GC-MS or LC-MS/MS analysis. 8-Dehydrocholesterol is quantified alongside cholesterol and other sterol intermediates.
|
| Cell Assay |
No cell-based assays are typically performed with 8-dehydrocholesterol as it is used as an analytical standard or biomarker. For cell culture studies, cells (e.g., fibroblasts from SLOS patients) can be cultured and sterol content analyzed to study cholesterol biosynthesis. Cells are cultured in medium containing delipidated serum and treated with compounds affecting cholesterol synthesis; sterols are extracted and analyzed by HPLC or LC-MS/MS.
|
| Animal Protocol |
8-Dehydrocholesterol is not administered to animals as a therapeutic agent. It is used as a biomarker in animal models of SLOS or cholesterol metabolism disorders. In such models, plasma or tissue sterol levels are measured to assess disease progression or treatment efficacy. Blood samples are collected, sterols are extracted, and 8-dehydrocholesterol levels are quantified by LC-MS/MS or GC-MS alongside other sterol markers (7-dehydrocholesterol, cholesterol, lathosterol).
|
| ADME/Pharmacokinetics |
8-Dehydrocholesterol (C2₇H44O, MW 384.65) is a lipophilic sterol compound. It is soluble in organic solvents such as chloroform, methanol, and hexane. The compound is stable when stored at -20degC under inert atmosphere. As a sterol intermediate, it is present in very low concentrations in normal tissues and is elevated in SLOS.
|
| Toxicity/Toxicokinetics |
8-Dehydrocholesterol is an endogenous sterol and is not associated with direct toxicity. Elevated levels are a consequence of SLOS rather than a cause of toxicity. The compound is not a therapeutic agent; it is a research compound and biomarker for sterol metabolism disorders.
|
| References | |
| Additional Infomation |
8-Dehydrocholesterol is a steroid.
8-Dehydrocholesterol (8-DHC) is a sterol intermediate in the cholesterol biosynthesis pathway and a diagnostic biomarker for Smith-Lemli-Opitz syndrome (SLOS). It accumulates in tissues and plasma when 7-dehydrocholesterol reductase (DHCR7) is deficient. The compound is not a drug target but is used as a research tool for studying cholesterol metabolism and as a biomarker for SLOS diagnosis and monitoring. It is available as a research-grade compound for analytical and biochemical studies. |
| Molecular Formula |
C27H44O
|
|---|---|
| Molecular Weight |
384.63766
|
| Exact Mass |
384.339
|
| CAS # |
70741-38-7
|
| PubChem CID |
129846
|
| Appearance |
White to off-white solid powder
|
| LogP |
7.452
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
655
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC3=C2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
|
| InChi Key |
VUKORTMHZDZZFR-BXAZICILSA-N
|
| InChi Code |
InChI=1S/C27H44O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21,23-24,28H,6-8,10-17H2,1-5H3/t19-,21+,23-,24+,26+,27-/m1/s1
|
| Chemical Name |
(3S,10S,13R,14R,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5.56 mg/mL (~14.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5998 mL | 12.9992 mL | 25.9983 mL | |
| 5 mM | 0.5200 mL | 2.5998 mL | 5.1997 mL | |
| 10 mM | 0.2600 mL | 1.2999 mL | 2.5998 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
